Reprogramming Myeloid Cells in Cancer: A New Challenge in Medicine

Dear Colleagues,

Since the beginning of this decade, antitumor immunotherapy has been recognized as a potent treatment option for several solid cancers such as melanoma, lung, renal cell, head and neck, colorectal, liver, bladder, gastric, cervical, urothelial, and breast next to hematological malignancies. The most common within the immunotherapeutic arsenal is represented by the immune checkpoint inhibitors. So far, their efficacy has been linked to tumor mutational burden, tumor cell-specific checkpoint positivity, abundance of tumor-infiltrating T cells, and an immune evasion profile. However, several recent studies have reported on the dual role of tumor infiltrating myeloid cells (TIMs). Not only have their abundance and suppressive functions within the tumor microenvironment have been linked to tumor progression, they can be highly positive for certain immune checkpoints. In addition, their capacity to recognize monoclonal antibodies via their Fc-receptors has been linked to antibody-dependent cellular cytotoxicity as well as the phenomenon of hyper-progression. As such, research into the exact role of tumor-infiltrating myeloid cells as well as strategies that aim to reprogram the TIMs in order to enhance the overall therapeutic effect are of utmost importance to further advance the exciting field of antitumor immunotherapy.

Dr. Cleo Goyvaerts
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.